Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohortM. Kandel, Isabelle Borget, Clara Allayous et al.|European Journal of Cancer|2018Cited by 38
Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohortPauline Tétu, Célèste Lebbé, Pierre‐Emmanuel Stoebner et al.|European Journal of Cancer|2019Cited by 35
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case–control studyLéo Plaçais, Célèste Lebbé, Stéphane Dalle et al.|Annals of the Rheumatic Diseases|2022Cited by 34
Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data☆Y. Di Filippo, Henri Montaudié, Stéphane Dalle et al.|Annals of Oncology|2020Cited by 30
Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National CohortManon Girod, O. Dereure, Stéphane Dalle et al.|JCO Precision Oncology|2022Cited by 14